Advertisement
Advertisement

LYEL

LYEL logo

Lyell Immunopharma, Inc. Common Stock

14.71
USD
Sponsored
+0.50
+3.52%
Aug 07, 15:59 UTC -4
Closed
exchange

After-Market

14.73

+0.02
+0.14%

Lyell Immunopharma, Inc. Common Stock Profile

About

Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.

Info & Links

CEO

Lynn Seely

Headquarters

201 HASKINS WAY
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.lyell.com

Auditor

Ernst & Young LLP

Share holders

63

Employees

161

Lyell Immunopharma, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

360.95M

Enterprise Value

287.96M

Enterprise Value/EBITDA(ttm)

-1.15

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

13.35K

Price to Book(mrq)

1.25

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-920285.25%

Profit Margin(ttm)

-1232720.57%

Return on Equity(ttm)

-87.60%

Return on Invested Capital(ttm)

-96.47%

Return on Assets(ttm)

-67.85%

Income Statement

Revenue(ttm)

27.00K

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

27.00K

EBITDA(ttm)3

-250.75M

Net Income Available to Common(ttm)

-248.48M

Diluted EPS(ttm)

-12.83

Share Statistics

Beta (5Y Monthly)

-0.04

52-Week Change

29.95%

S&P 500 52-Week Change

21.72%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

24.51M

Dividend Yield

0.00%

Float4

22.98M

% Held by Insiders

6.20%

% Held by Institutions

66.05%

Balance Sheet

Total Cash(mrq)

204.10M

Total Cash Per Share(mrq)

8.33

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.36%

Quick Ratio(mrq)

7.23%

Book Value Per Share(mrq)

9.99

Cash Flow

Operating Cash Flow Per Share(ytd)

-3.10

Free Cash Flow(ytd)

-72.77M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement